Oncology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

MicroRNA expression, survival, and response to Interferon in liver cancer
New England Journal of Medicine, 10/08/09

Ji J et al. – The expression patterns of microRNAs in liver tissue differ between men and women with hepatocellular carcinoma. The miR-26 expression status of such patients is associated with survival and response to adjuvant therapy with interferon alfa.

Methods

Analyzed 3 independent cohorts that included total of 455 patients with hepatocellular carcinoma who had undergone radical tumor resection between 1999 and 2003
MicroRNA-expression profiling performed in cohort of 241 patients with hepatocellular carcinoma to identify tumor-related microRNAs and determine association with survival in men and women
Used quantitative reverse-transcriptase–polymerase-chain-reaction assays to measure microRNAs and assess their association with survival and response to therapy with interferon alfa in 214 patients from 2 independent, prospective, randomized, controlled trials of adjuvant interferon therapy

Results

In hepatocellular carcinoma, expression of miR-26a and miR-26b in nontumor liver tissue higher in women than in men
Tumors had reduced levels of miR-26 expression, as compared with paired noncancerous tissues
Level of miR-26 expression also associated with hepatocellular carcinoma
Tumors with reduced miR-26 expression had a distinct transcriptomic pattern, and analyses of gene networks revealed activation of signaling pathways between nuclear factor B and interleukin-6 might play a role in tumor development
Patients whose tumors had low miR-26 expression had shorter overall survival but better response to interferon therapy than did patients whose tumors had high expression of the microRNA

<< Previous
Underweight and breast cancer recurrence and death: A report from...

Next >>
Ovarian ablation by radiation therapy: Is it still an option for...